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arly randomized clinical trials of primary prevention implantable cardioverter defibrillators (ICDs) in patients with nonischemic cardiomyopathy failed to establish survival benefit from this therapy; however, those trials were too small to provide definitive results. 1, 2 When the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) was published in 2005, it was practice changing. SCD-HeFT showed that primary prevention ICDs significantly improve the survival of patients with a left ventricular ejection fraction ≤35% attributable to ischemic or nonischemic cardiomyopathy and New York Heart Association class II or III heart failure symptoms despite optimal medical therapy. 3 Patients with nonischemic cardiomyopathy constituted about half of the 2521 total enrolled patients in SCD-HeFT. 3 The results of SCD-HeFT formed the basis of a class I guideline recommendation for primary prevention ICDs in patients with New York Heart Association class II or III heart failure symptoms and a left ventricular ejection fraction ≤35% attributable to nonischemic cardiomyopathy, 4,5 a recommendation that has not changed since 2005. The role of primary prevention ICDs in patients with nonischemic cardiomyopathy was called into question with the recent publication of the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients with Nonischemic Systolic Heart Failure on Mortality). 6 This trial enrolled patients with New York Heart Association class II or III heart failure symptoms (or New York Heart Association class IV if cardiac resynchronization therapy [CRT] was planned) with a left ventricular ejection fraction ≤35% attributable to nonischemic cardiomyopathy and an increased level of N-terminal pro-brain natriuretic peptide. Participants were required to be on guideline-directed medical therapy. 6 The DANISH trial showed a reduction in sudden cardiac death (SCD), but not in all-cause mortality in patients randomly assigned to an ICD. A subgroup analysis reported in the main DANISH article suggested survival benefit of ICDs in patients <59 years of age but not in patients older than this age cutoff. 6 The relationship between age and outcomes of ICDs in DANISH was further explored and characterized in an article by Elming and colleagues published in this issue of Circulation. 7 Elming and colleagues analyzed 1116 patients enrolled in the DANISH trial to assess the association between the ICD and mortality by age and to explore an optimal age cutoff for ICD implantation. Modes of death were classified into SCD and non-SCD and compared between younger and older patients. They found a linear relationship between older age and diminished benefit from ICD and identified an optimal age cutoff for ICD implantation of ≤70 years. The ICD was associated with a significant 30% relative risk reduction in all-cause mortality in patients ≤70 years but no mortality benefit in patients >70 years. The data on mode of death were quite informative because the risk of SCD and non-SCD in patients ≤70 years was 1.8 (1.3-2.5) and 2.7 (2.1-3.5) events/100 patient-years, respectively. In contrast, among patients >70 years of age, the risk of SCD and non-SCD was 1.6 (0.8-3.2) and 5.4 (3.7-7.8) events/100 patient-years, respectively. The difference in non-SCD between the 2 age groups was statistically significant. The authors concluded that younger patients appear to benefit more from a primary prevention ICD than older patients and that this finding is likely because SCD accounted for a higher proportion of death in younger patients. 7 Conventional wisdom in clinical research is to beware of subgroup analyses. However, there are several features of the current analysis that should prompt one to pause before dismissing the results as chance findings. First, this analysis of ICD benefit by age was prespecified. Second, the statistical methods used in this analysis were fairly robust. Third, there are several findings in the article that align well and support the main conclusions. Older patients had a significantly higher prevalence of comorbidities such as more advanced heart failure, atrial fibrillation, and hypertension. They also had appreciably higher median Nterminal pro-brain natriuretic peptide, longer median QRS duration, and a lower glomerular filtration rate. Older patients also had significantly longer duration of heart failure at enrollment (25 months versus 12 months for patients <59 years old). One would expect these findings to bias the results toward a higher risk of non-SCD in these patients, which is exactly what the investigators found. Because the risk of non-SCD is not treatable by an ICD, it is not surprising that the investigators found no association between ICDs and improved survival. 7 Concordant with the findings by Elming and colleagues, 7 prior work on ICDs and age suggested that the survival benefit of ICDs is attenuated in older patients (defined as ≥75 years old). 8 However, chronological age is only one of several factors that influence the effectiveness of ICDs. Other pertinent factors that should be considered in deciding on whether or not to offer a patient an ICD include the number, type, and severity of comorbidities, frailty, functional status, and quality of life. Professional guidelines state that ICD implantation is not recommended if meaningful survival of >1 year is not expected. Other very important factors that should be considered before recommending an ICD are patients' preferences, values, and health goals. Patients' interest in an invasive procedure such as ICD implantation and their acceptance of SCD risk vary and may evolve as their underlying diseases progress. One cannot overemphasize the importance of shared decision making in this process in which the best evidence on benefits and risks of a given procedure is paired with a clear understanding and an open discussion of the patient's preferences. This approach should be adopted regardless of the patient's age.
Another interesting and plausible explanation for the findings by Elming and colleagues is the significantly higher use of CRT in older patients (65% versus 52% in patients <59 years of age). 7 The DANISH trial allowed implantation of a CRT device in all patients if they were eligible for this therapy; if patients were randomly assigned to the ICD arm, they received a CRT-defibrillator device, and if they were randomly assigned to the medical therapy arm, they received a CRT-pacemaker device. 6 Given that 65% of older patients received a CRT device, it is very possible that the ICD effect on survival was diluted by the use of CRT in both arms, resulting in insufficient statistical power to show a difference in survival with an ICD in patients who did not qualify for a CRT. Therefore, the results of the main DANISH trial and this secondary analysis on age likely do not generalize to patients with nonischemic cardiomyopathy who are not eligible for a CRT device. Indeed, several meta-analyses have examined the role of primary prevention ICDs (with no CRT) in patients with nonischemic cardiomyopathy, and they have generally found a significant relative risk reduction of ≈25% in all-cause mortality with an ICD. [9] [10] [11] Another clear difference between SCD-HeFT and DANISH is the significantly lower rate of mortality in the overall patient population of the DANISH trial that may be, at least in part, attributable to the excellent medical therapy patients received in DANISH that is difficult to achieve in clinical practice.
So, what should clinicians do in light of the results of this article by Elming and colleagues? In patients with a left ventricular ejection fraction ≤35% attributable to nonischemic cardiomyopathy who are ≤70 years of age, clinicians should continue to recommend an ICD provided meaningful survival of >1 year is expected. In similar patients who are >70 years of age and who qualify for a CRT device, a discussion of the pros and cons of a CRT-pacemaker versus CRT-defibrillator in light of the current findings is in order. In similar patients who are >70 years of age but who do not qualify for a CRT device, further research is needed to better understand the outcomes of primary prevention ICDs and to help refine patient selection for this therapy based on their risk of SCD versus non-SCD. After all, the mean or median age of patients enrolled in prior randomized clinical trials of primary prevention ICDs in patients with nonischemic cardiomyopathy ranged from 52 years in the Cardiomyopathy Trial to 60 years in SCD-HeFT. 1, 3 So, patients >70 years of age were not well represented in those trials. Until more data on ICD efficacy or effectiveness are available for patients with nonischemic cardiomyopathy who are >70 years of age, individualized decisions regarding ICDs should be made that take into account the patient's level of comorbidity, frailty, functional status, and healthcare goals and preferences.
